NCT02635672: Phase I Dose Escalation Study for BAY 1251152 in Patients With Advanced Cancer

NCT02635672
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MYC
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with new or progressive brain, meningeal, or spinal metastases
https://ClinicalTrials.gov/show/NCT02635672

Comments are closed.

Up ↑